In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance.
Wirth AK, Wange L, Vosberg S, Henrich KO, Rausch C, Özdemir E, Zeller CM, Richter D, Feuchtinger T, Kaller M, Hermeking H, Greif PA, Senft D, Jurinovic V, Bahrami E, Jayavelu AK, Westermann F, Mann M, Enard W, Herold T, Jeremias I.
Wirth AK, et al. Among authors: kaller m.
Leukemia. 2022 Dec;36(12):2863-2874. doi: 10.1038/s41375-022-01726-7. Epub 2022 Nov 4.
Leukemia. 2022.
PMID: 36333584
Free PMC article.